drugset
drugset / Trial / NCT06312020

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

NCT06312020 ↗

Phase 2 Terminated 209 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Timeline

Start
2024-05-09
Primary completion
2026-04-28
Completion
2026-04-28

Outcome

Outcome not reported

Stopped: “The study was terminated by sponsor due to meeting pre-defined criteria for futility.”

Drugs

EvaluationDrugModalityDoseRoute
Subject HZN-1116 Unknown — Subcutaneous

Indications

Sjogren syndrome